191 related articles for article (PubMed ID: 35665957)
1. Design, synthesis, biological evaluation, and in silico studies of 2-aminobenzothiazole derivatives as potent PI3Kα inhibitors.
Haider K; Ahmad K; Najmi AK; Das S; Joseph A; Shahar Yar M
Arch Pharm (Weinheim); 2022 Oct; 355(10):e2200146. PubMed ID: 35665957
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis and Biological Evaluation of 6-(Imidazo[1,2-a]pyridin-6-yl)quinazoline Derivatives as Anticancer Agents via PI3Kα Inhibition.
Li M; Wang D; Li Q; Luo F; Zhong T; Wu H; Xiong L; Yuan M; Su M; Fan Y
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047827
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
Wang ZX; Wang S; Qiao XP; Li WB; Shi JT; Wang YR; Chen SW
Bioorg Med Chem; 2022 Nov; 74():117067. PubMed ID: 36272186
[TBL] [Abstract][Full Text] [Related]
4. Ligand-Based Drug Design: Synthesis and Biological Evaluation of Substituted Benzoin Derivatives as Potential Antitumor Agents.
Sabbah DA; Ibrahim AH; Talib WH; Alqaisi KM; Sweidan K; Bardaweel SK; Sheikha GA; Zhong HA; Al-Shalabi E; Khalaf RA; Mubarak MS
Med Chem; 2019; 15(4):417-429. PubMed ID: 30207238
[TBL] [Abstract][Full Text] [Related]
5. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
Shaheen MA; El-Emam AA; El-Gohary NS
Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss.
Xu S; Luo L; Sun X; Yang Y; Guo Q; Jiang Z; Wu Y
Bioorg Med Chem; 2023 Jan; 78():117133. PubMed ID: 36599263
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and evaluation of 2, 6, 8-substituted Imidazopyridine derivatives as potent PI3K
Chen R; Wang Z; Sima L; Cheng H; Luo B; Wang J; Guo B; Mao S; Zhou Z; Peng J; Tang L; Liu X; Liao W
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2155638. PubMed ID: 36650905
[TBL] [Abstract][Full Text] [Related]
9. Structure-based drug design, synthesis, and biological evaluation of novel 1,3,5-triazine or pyrimidine derivatives containing benzoyl hydrazine moiety as PI3Kα selective inhibitors.
Fu S; Liu J; Li C; Wei J; Yue H; Yang A; Wang K; Wu Y; Hou Y; Zhao Y
Bioorg Chem; 2023 Nov; 140():106738. PubMed ID: 37562315
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Design: Synthesis, X-ray Crystallography, and Biological Evaluation of N-Substituted-4-Hydroxy-2-Quinolone-3-Carboxamides as Potential Cytotoxic Agents.
Sabbah DA; Hishmah B; Sweidan K; Bardaweel S; AlDamen M; Zhong HA; Abu Khalaf R; Hasan Ibrahim A; Al-Qirim T; Abu Sheikha G; Mubarak MS
Anticancer Agents Med Chem; 2018; 18(2):263-276. PubMed ID: 28901259
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates containing sulfonamido as potential PI3Kα inhibitors.
Yin Y; Hu JQ; Wu X; Sha S; Wang SF; Qiao F; Song ZC; Zhu HL
Bioorg Med Chem; 2019 Jun; 27(11):2261-2267. PubMed ID: 31029551
[TBL] [Abstract][Full Text] [Related]
12. Novel Coumarin-furo[2,3-d]pyrimidinone hybrid derivatives as anticancer agents: Synthesis, biological evaluation and molecular docking.
Jin Y; He S; Wu F; Luo C; Ma J; Hu Y
Eur J Pharm Sci; 2023 Sep; 188():106520. PubMed ID: 37423580
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and evaluation of acridone-2-carbohydrazide derivatives as p-AKT Ser
Yadav TT; Kumar MS; Bajaj S; Yc M
Future Med Chem; 2023 Apr; 15(8):699-716. PubMed ID: 37170843
[No Abstract] [Full Text] [Related]
14. Novel 1,3,4-thiadiazole/oxadiazole-linked honokiol derivatives suppress cancer via inducing PI3K/Akt/mTOR-dependent autophagy.
Xu T; Tian W; Zhang Q; Liu J; Liu Z; Jin J; Guo Y; Bai LP
Bioorg Chem; 2021 Oct; 115():105257. PubMed ID: 34426156
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, anticancer and antimicrobial evaluation of new benzofuran based derivatives: PI3K inhibition, quorum sensing and molecular modeling study.
El-Khouly OA; Henen MA; El-Sayed MA; Shabaan MI; El-Messery SM
Bioorg Med Chem; 2021 Feb; 31():115976. PubMed ID: 33388654
[TBL] [Abstract][Full Text] [Related]
16. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, biological evaluation, and in silico studies of indole-tethered pyrazoline derivatives as anticancer agents targeting topoisomerase IIα.
Haider K; Sharma S; Pokharel YR; Das S; Joseph A; Najmi AK; Ahmad F; Yar MS
Drug Dev Res; 2022 Nov; 83(7):1555-1577. PubMed ID: 35898169
[TBL] [Abstract][Full Text] [Related]
19. Development and Assessment of 1,5-Diarylpyrazole/Oxime Hybrids Targeting EGFR and JNK-2 as Antiproliferative Agents: A Comprehensive Study through Synthesis, Molecular Docking, and Evaluation.
Abdelrahman KS; Hassan HA; Abdel-Aziz SA; Marzouk AA; Shams R; Osawa K; Abdel-Aziz M; Konno H
Molecules; 2023 Sep; 28(18):. PubMed ID: 37764297
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
